Skip to main content
Premium Trial:

Request an Annual Quote

AstraZeneca, ArcherDx Partner on Minimal Residual Disease Monitoring for Lung Cancer Drug Trials

NEW YORK – ArcherDx and AstraZeneca have formed a strategic collaboration to develop assays to detect minimal residual disease (MRD) in patients with early-stage non-small cell lung cancer, the companies said on Tuesday.

Under the terms of the agreement, Boulder, Colorado-based ArcherDx will perform exome sequencing of resected non-small cell lung cancer patient samples and generate patient-specific, research-use-only circulating tumor DNA assays.

ArcherDx's assay will be used in AstraZeneca's recently launched Phase III MERMAID-1 trial to evaluate the effect of adjuvant treatment with durvalumab (Imfinzi) plus chemotherapy versus chemotherapy alone on disease-free survival. The trial is in patients with completely resected, stage II and III NSCLC who show evidence of MRD suggesting a high risk of relapse.

ArcherDx said that it plans to use these assays to develop companion diagnostics for AstraZeneca's therapies, and together the companies will seek global regulatory approval pending the successful completion of Phase 3 trials. The ongoing development of these assays is informed by the TRACERx study, funded by Cancer Research UK and led by University College London and the Francis Crick Institute.

"MERMAID-1 is a novel randomized trial using ctDNA to identify patients at high risk of recurrence after surgery who may benefit from intervention with immunotherapy," Charles Swanton, professor at UCL and the Francis Crick Institute, chief clinician at CRUK, and coordinating investigator on MERMAID-1, said in a statement. "We hope this approach will lead to better patient outcomes by intensifying treatment for patients most likely to relapse, while avoiding additional chemotherapy after surgery when not needed."

José Baselga, executive vice president of oncology R&D at AstraZeneca, noted in a statement that while detecting and monitoring for MRD "has proven challenging in solid tumors, the MERMAID-1 trial and this partnership stand to break new ground in lung cancer."

The master collaboration agreement also allows for expansion into additional disease indications and therapeutic categories, ArcherDx said. Financial terms of the agreement were not disclosed.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more